artisteer / iStockphoto.com
An EU court ruling on gene-editing regulation has sparked widespread concerns in the scientific and legal communities, as LSIPR finds out.
In late July, Europe’s highest court handed down a much-awaited ruling on gene-editing which was met by an uproar from parts of the scientific community.
For Huw Jones, professor of translational genomics for plant breeding at Aberystwyth University in Wales, the EU has essentially “turned back the clock on innovation”. This is unlike many other countries that have signalled that, with certain conditions, gene-edited crops are not be regulated by genetically modified organisms (GMO) laws.
After awaiting regulatory clarification for years, researchers and developers were shocked by the court’s decision to subject genome-editing techniques, including CRISPR/Cas9, to more stringent regulations.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office